Native Antigen Company (NAC) ZikaThe Native Antigen Company (NAC) has relocated into larger facilities, in Oxfordshire, UK.

The new building has purpose-built laboratories and doubles the company’s manufacturing capacity.

This will increase the speed of new product development within NAC’s core business of infectious disease antigens and antibodies.

The new laboratory space also enables NAC to add custom immunoassays to its offering to support customer’s ELISA assay and lateral flow device requirements.

The new suite of laboratories has been established to satisfy increasing commercial demands and accommodate NAC’s growing R&D pipeline.

The move facilitates the expansion of the company’s custom services for recombinant protein production, based on its proprietary mammalian cell expression system.

The HEK293 expression system used at NAC has been used to prepare a wide range of complex recombinant proteins, that have been shown to be glycosylated and to demonstrate functional activity.

Dr Nick Roesen, Chief Scientific Officer, NAC, said: “I am delighted with the new facilities and the increased capacity that they provide. The addition of immunoassay development services will enable our customers to work with us from protein expression through to development of an immunoassay for a specific protein.”

“In providing this new service we aim to fill the gap between small-scale R&D expression and high-end pharmaceutical scale GMP manufacturing. We are excited to offer this to our customers, while at the same time progressing our own new product pipeline for infectious disease antigens and anitbodies.”